VOZMOZhNOSTI ENTEROKINETIChESKOY TERAPII NARUShENIY MOTORIKI KIShEChNIKA PRI ZAPORE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article considers the epidemiology, causes, and problems in the diagnosis of constipation. Treatment of functional constipation is discussed in detail. Key importance in the development of constipation belongs to a violation of the motor function of the colon characterized by ineffective colonic transit. Among the various neurotransmitters that affect motor function of the colon, serotonin (5-HT) occupies the central place. Providing a variety of effects in the gastrointestinal tract, it also regulates intestinal propulsive activity through serotonin receptors type 4 (5-HT4). The impact on these receptors is the most physiological way to restore the impaired motor activity of the colon, underlying symptoms of chronic constipation.

Full Text

Restricted Access

About the authors

O. A Sablin

References

  1. Лазебник Л.Б., Прилепская С.И., Барышников Е.Н., Парфенов А.И., Косачева Т.Н. Распространенность и факторы риска запоров у взрослого населения Москвы // Экспериментальная и клиническая гастроэнтерология 2011. № 3. С. 68-73.
  2. Agrawal S, Bhupinderjit A, Bhutani MS, et al. Colorectal cancer in African Americans. Am J Gastroenterol 2005;100:515-23.
  3. Brandt LJ, Prather CM, Quigley EM, et al. Systematic review on the management of chronic constipation in North America. Am J Gastroenterol 2005;100(S.1):S5-21.
  4. Camilleri M, Cryp RS, Kerstens R, Vandeplassche L. Efficacy of 12-Week Treatment with Prucalopride (Resolor®) in Patients with Chronic Constipation: Combined Results of Three Identical Randomized, Double-Blind, Placebo-Controlled Phase III Trials. Gastroenterology 2008;134(S.1):A548.
  5. Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008;358:2344-54.
  6. Camilleri M, Beyens G, Kerstens R, Robinson P, Vandeplassche L. Safety assessment of prucalopride in elderly patients with potential applications. Therap Adv Gastroenterol 2012;5(1):23-30.
  7. Eoff J, Lembo A. Optimal Treatment of Chronic Constipation in Managed Care: Review and Roundtable Discussion. Manag Care Pharm 2008;14:1-15.
  8. Ford AC, Suares NC. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: a systematic review and metaanalysis. Gut 2011;60:209-18.
  9. Gershon MD, Tack J. The Serotonin Signaling System: From Basic Understanding To Drug Development for Functional GI Disorders. Gastroenterology 2007;132:397-414.
  10. Johanson J, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther 2007;25:599-608.
  11. Johnson DE, Drummond E, Grimwood S, et al. The 5-hydroxytryptamine 4 receptor agonists prucalopride and PRX-03140 increase acetylcholine and histamine levels in the rat prefrontal cortex and the power of stimulated hippocampal в oscillations. J Pharmacol Exp Ther 2012;341(3):681-91.
  12. Krogh K, Jensen MB, Gandrup P, et al. Efficacy and tolerability of prucalopride in patients with constipation due to spinal cord injury. Scand J constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil 2009;21: 1256-e117.
  13. Camilleri M, Van Outryve MJ, Beyens G, et al. Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation - follow-up of patients from the pivotal studies. Aliment Pharmacol Ther 2010;32(9):1113-23.
  14. Cash BD, Chey WD. The role of serotonergic agents in the treatment of patients with primary chronic constipation. Aliment Pharmacol Ther 2005;22(11-12):1047-60.
  15. Coremans G, Kerstens R, De Pauw M, Stevens M. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a doubleblind, placebo-controlled clinical trial. Digestion 2003;67(1-2):82-9.
  16. De Maeyer JH, Lebebvre RA, Schuurkes JA. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil 2008; 20:99-112.
  17. Drossman DA. The Functional Gastrointestinal Disorders and the Rome III Process. Gastroenterology 2006;130(5):1377-90.
  18. Quigley EM. Prucalopride: safety, efficacy and Gastroenterol 2002;37:431-36.
  19. Muller-Lissner S, Rykx A, Kersten R, Vandeplassche L. A double blind, placebo controlled study of prucalopride in elderly patients with chronic constipation. Neurogastro Motil 2010;22:991-98.
  20. Pare P, Bridges R, Champion MC, et al. Recommendations on chronic constipation (including constipation associated with irritable bowel syndrome) treatment. Can J Gastroenterol 2007;21(Suppl B):3B-22B.
  21. Quigley EM, Vandeplassche L, Kerstens R, et al. Clinical trial: the effcacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation - a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009; 29:315-28.
  22. Quigley EM. Prucalopride: safety, efficacy and potential applications. Ther Adv Gastroenterol 2012;5(1):23-30.
  23. Scarpignato C. Commentary: towards a cardiac safe prokinetic. Aliment Pharmacol Ther 2012;35(10):1243-44.
  24. Sloots CE, Rykx A, Cools M, Kerstens R, De Pauw M. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci 2010;55:2912-21.
  25. Stanghellini V, Vandeplassche L, Kerstens R. Best response distribution of 12-week treatment with prucalopride (Resolor) in patients with chronic constipation: combined results of three randomised, double-blind, placebo-controlled phase iii trials. Gut 2011;60: A159-60.
  26. Sarna SK. Colonic Motility: From Bench Side to Bedside. San Rafael (CA): Morgan & Claypool Life Sciences. 2010.
  27. Tack J, van Outryve M, Beyens G, Kerstens R, Vandeplassche L. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut;2009;58(3):357-65.
  28. Tack J, Kerstens R, Ausma J, Beyens G, Vandeplassche L. Safety and tolerability of prucalopride [Resolor®] in patients with chronic constipation: pooled data from three pivotal phase III studies, Digestive Disease Week (DDW), May 17-22, 2008, T1322.
  29. Van de Velde V, Vandeplassche L, Van Dijck W, et al. Effects of moderate or severe hepatic impairment on the pharmacokinetics of prucalopride. Gut 2012;61(S.3):A306.
  30. Wald A, Scarpignato C, Mueller-Lissner S, et al. A multinational survey of prevalence and patterns of laxative use among adults with selfdefined constipation. Aliment Pharmacol Ther 2008;28:917-30.
  31. Wald A. Motility disorders of the colon and rectum. Curr Opin Gastroenterol 2012; 28(1):52-6.
  32. Yost KJ, Haan MN, Levine RA, et al. Comparing SF-36 scores across three groups of women with different health profiles. Qual Life Res 2005;14:1251-61.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies